Antibiotic therapy for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in surgical wounds

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 8, 2013, Pages

  Gurusamy, Kurinchi Selvan ^a   Koti, Rahul ^a   Toon, Clare D ^b   Wilson, Peter ^c   Davidson, Brian R ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b WEST SUSSEX COUNTY COUNCIL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; LINEZOLID; VANCOMYCIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ANTIBIOTIC THERAPY; HOSPITALIZATION; HUMAN; INTENTION TO TREAT ANALYSIS; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SURGICAL INFECTION; SYSTEMATIC REVIEW; INTRAVENOUS DRUG ADMINISTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STAPHYLOCOCCUS INFECTION; STAPHYLOCOCCAL INFECTIONS; SURGICAL WOUND INFECTION;

ACETAMIDES; ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OXAZOLIDINONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STAPHYLOCOCCAL INFECTIONS; SURGICAL WOUND INFECTION; VANCOMYCIN;

EID: 84893411090     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009726.pub2     Document Type: Review

References (63)

1. Weigelt J, Kaafarani HM, Itani KM, Swanson RN. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. American Journal of Surgery 2004;188(6):760-6.
2. Jacqueline C, Amador G, Desessard C, Le Mabecque V, Miegeville AF, Caillon J, et al. Assessment of linezolid, vancomycin, and rifampicin as monotherapy in comparison with combination of linezolid/rifampicin and vancomycin/rifampicin in the treatment of methicillin-resistant Staphylococcus aureus acute osteomyelitis. Clinical Microbiology and Infection 2011;17(Supplement S4):S428.
3. Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clinical Therapeutics 2008;30(5):868-83.
4. Philpott-Howard J, Burroughs A, Fisher N, Hastings M, Kibbler C, Mutimer D, et al. Piperacillin-tazobactam versus ciprofloxacin plus amoxicillin in the treatment of infective episodes after liver transplantation. Journal of Antimicrobial Chemotherapy 2003;52:993-1000.
5. Van Laethem Y, Hermans P, De Wit S, Goosens H, Clumeck N. Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results. Journal of Antimicrobial Chemotherapy 1988;21(Supplement A):81-7.
6. Barber M. Methicillin-resistant staphylococci. Journal of Clinical Pathology 1961 Jul;14:385-93.
7. Chemaly RF, Hachem RY, Husni RN, Bahna B, Rjaili GA, Waked A, et al. Characteristics and outcomes of methicillin-resistant Staphylococcus aureus surgical-site infections in patients with cancer: a case-control study. Annals of Surgical Oncology 2010;17(6):1499-506.
8. Deeks JJ, Higgins JPT, Altman DG, on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group (Editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
9. DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50.
10. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
11. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clinical Microbiology Reviews 2002;15(2):167-93.
12. ECDC. European Centre for Disease Prevention and Control. Annual epidemiological report on communicable diseases in Europe. http://www.ecdc.europa.eu/en/publications/Publications/0910_SUR_Annual_Epidemiological_Report_on_Communicable_Diseases_in_Europe.pdf 2009 (accessed on 17 June 2011).
13. ECDC. European Centre for Disease Prevention and Control. The bacterial challenge: Time to react. A call to narrow the gap between multi-drug resistant bacteria in the EU and the development of new anti-bacterial agents. http://www.ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf 2009 (accessed on 17 June 2011).
14. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
15. Fraser S, Brady R, Graham C, Paterson-Brown S, Gibb A. Methicillin-resistant Staphylococcus aureus in surgical patients: identification of high-risk populations for the development of targeted screening programmes. Annals of the Royal College of Surgeons of England 2010;92(4):311-5.
16. Gurusamy KS, Gluud C, Nikolova D, Davidson BR. Assessment of risk of bias in randomized clinical trials in surgery. British Journal of Surgery 2009;96(4):342-9.
17. Gurusamy KS, Koti R, Toon C, Wilson P, Davidson BR. Antibiotic therapy for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) in non-surgical wounds. Cochrane Database of Systematic Reviews In press.
18. Gurusamy KS, Koti R, Wilson P, Davidson BR. Antibiotic prophylaxis for the prevention of methicillin-resistant Staphylococcus aureus (MRSA) related complications in surgical patients. Cochrane Database of Systematic Reviews In press.
19. Harbarth S, Huttner B, Gervaz P, Fankhauser C, Chraiti MN, Schrenzel J, et al. Risk factors for methicillin-resistant Staphylococcus aureus surgical site infection. Infection Control and Hospital Epidemiology 2008;29(9):890-3.
20. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
21. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
22. Higgins JPT, Altman DG, on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group (Editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
23. Higgins JPT, Deeks JJ and Altman DG on behalf of the Cochrane Statistical Methods Group (Editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
24. Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infection Control and Hospital Epidemiology 1992;13(10):606-8.
25. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Code of Federal Regulation & ICH Guidelines. Media: Parexel Barnett, 1996.
26. Jevons PM. 'Celbenin' - resistant staphylococci. British Medical Journal 1961;1(5219):124-5.
27. Kallen AJ, Mu Y, Bulens S, Reingold A, Petit S, Gershman K, et al. Health care-associated invasive MRSA infections, 2005-2008. JAMA 2010;304(6):641-8.
28. Kang CI, Song JH, Ko KS, Chung DR, Peck KR. Clinical features and outcomes of Staphylococcus aureus infections in non-neutropenic cancer patients. Supportive Care in Cancer 2012;20(3):483-8.
29. Kaye KS, Anderson DJ, Choi Y, Link K, Thacker P, Sexton DJ. The deadly toll of invasive methicillin-resistant Staphylococcus aureus infection in community hospitals. Clinical Infectious Diseases 2008;46(10):1568-77.
30. Keel RA, Schaeftlein A, Kloft C, Pope JS, Knauft RF, Muhlebach M, et al. Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Antimicrobial Agents and Chemotherapy 2011;55(7):3393-8.
31. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
32. Klimek JJ, Marsik FJ, Bartlett RC, Weir B, Shea P, Quintiliani R. Clinical, epidemiologic and bacteriologic observations of an outbreak of methicillin-resistant Staphylococcus aureus at a large community hospital. American Journal of Medicine 1976;61(3):340-5.
33. Knox R, Smith JT. The nature of penicillin resistance in staphylococci. Lancet 1961;2(7201):520-2.
34. Kuehnert MJ, Hill HA, Kupronis BA, Tokars JI, Solomon SL, Jernigan DB. Methicillin-resistant-Staphylococcus aureus hospitalizations, United States. Emerging Infectious Diseases 2005;11(6):868-72.
35. Lamagni TL, Potz N, Powell D, Pebody R, Wilson J, Duckworth G. Mortality in patients with meticillin-resistant Staphylococcus aureus bacteraemia, England 2004-2005. Journal of Hospital Infection 2011;77(1):16-20.
36. Lefebvre C, Manheimer E, Glanville J, on behalf of the Cochrane Information Retrieval Methods Group. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
37. Lewis T, Chaudhry R, Nightingale P, Lambert P, Das I. Methicillin-resistant Staphylococcus aureus bacteremia: epidemiology, outcome, and laboratory characteristics in a tertiary referral center in the UK. International Journal of Infectious Diseases 2011;15(2):e131-5.
38. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clinical Infectious Diseases 2011;52(3):285-92.
39. Loeb MB, Main C, Eady A, Walkers-Dilks C. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD003340]
40. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Statistics in Medicine 2001;20(4):641-54.
41. Melzer M, Welch C. Outcomes in UK patients with hospital-acquired bacteraemia and the risk of catheter-associated urinary tract infections. Postgraduate Medical Journal 2013;Mar 21:Epub ahead of print. [DOI: 10.1136/postgradmedj-2012-131393]
42. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
43. Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. International Journal of Epidemiology 1992;21(5):837-41.
44. O'Toole RD, Drew WL, Dahlgren BJ, Beaty HN. An outbreak of methicillin-resistant Staphylococcus aureus infection. Observations in hospital and nursing home. JAMA 1970;213(2):257-63.
45. OED. Oxford English Dictionary. The definitive record of the English language. http://www.oed.com/2011 (accessed on 7th April, 2011).
46. Otter JA, French GL. Community-associated meticillin-resistant Staphylococcus aureus strains as a cause of healthcare-associated infection. Journal of Hospital Infection 2011;79(3):189-93.
47. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
48. Reddy SL, Grayson AD, Smith G, Warwick R, Chalmers JA. Methicillin resistant Staphylococcus aureus infections following cardiac surgery: incidence, impact and identifying adverse outcome traits. European Journal of Cardio-Thoracic Surgery 2007;32(1):113-7.
49. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
50. Ridgeway S, Wilson J, Charlet A, Kafatos G, Pearson A, Coello R. Infection of the surgical site after arthroplasty of the hip. Journal of Bone and Joint Surgery. British Volume 2005;87(6):844-50.
51. Sanchez CJ Jr, Mende K, Beckius ML, Akers KS, Romano DR, Wenke JC, et al. Biofilm formation by clinical isolates and the implications in chronic infections. BMC Infectious Diseases 2013;13:47.
52. Sanjay P, Fawzi A, Kulli C, Polignano FM, Tait IS. Impact of methicillin-resistant Staphylococcus Aureus (MRSA) infection on patient outcome after pancreatoduodenectomy (PD)--a cause for concern?. Pancreas 2010;39(8):1211-4.
53. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
54. Schunemann H, Brozek J, Oxman A, editors. Grade handbook for grading quality of evidence and strength of recommendation. Version 3.2 [updated March 2009]. The Grade Working Group, 2009. Available from http://www. Cc-ims. Net/gradepro.
55. Schunemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH (editors) on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Presenting results and Summary of findings tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
56. Shukla S, Nixon M, Acharya M, Korim MT, Pandey R. Incidence of MRSA surgical-site infection in MRSA carriers in an orthopaedic trauma unit. Journal of Bone and Joint Surgery. British Volume 2009;91(2):225-8.
57. Scottish Intercollegiate Guidelines Network (SIGN). Search filters. http://www.sign.ac.uk/methodology/filters.html#random 2011.
58. Skov R, Kolmos HJ, Peltonen R, Vuopio-Varkila J, Hardardottir H, Gudlaugsson O, et al. MRSA infections increasing in the Nordic countries. Eurosurveillance 2005;10(31):http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=2765.
59. Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. Journal of Infection 2009;59(Supplement 1):S59-74.
60. Wang JT, Wang JL, Fang CT, Chie WC, Lai MS, Lauderdale TL, et al. Risk factors for mortality of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection: with investigation of the potential role of community-associated MRSA strains. Journal of Infection 2010;61(6):449-57.
61. Watanabe A, Kohnoe S, Shimabukuro R, Yamanaka T, Iso Y, Baba H, et al. Risk factors associated with surgical site infection in upper and lower gastrointestinal surgery. Surgery Today 2008;38(5):404-12.
62. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336:601-5.
63. Wulf M, Voss A. MRSA in livestock animals-an epidemic waiting to happen?. Clinical Microbiology and Infection 2008;14(6):519-21.